Eli Lilly and Novo Nordisk have experienced massive stock gains, with Eli Lilly up 750% and Novo Nordisk 360% over the past five years, driven by the success of weight-loss drugs.
Read the full research in the app
A subscription is required to access the full thread.
Open in the app →